Skip to content
National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
Division of Cancer Prevention logo
Home Site Map Contact DCP
Programs & Resources

Meetings & Events

Trans-NIH Angiogenesis Workshop; May 20-21, 2013
  • Speaker Biosketches

    Portrait of James E. Faber, PhD

    James E. Faber, PhD
    (University of North Carolina, Chapel Hill, NC)


    Dr. James Faber's research focuses on the collateral circulation, angiogenesis and ischemic disease. His work has led to several patents and pendings on compounds for limiting excessive vascular growth, and currently on systems for evaluation of collateral extent in humans. Dr. Faber has published over 110 papers, chapters and reviews. He has been appointed to five editorial boards, served as associate editor of the American Journal of Physiology, currently serves on the boards of Circulation Research and Angiogenesis, has served on numerous grant review panels for NIH, serves on the programming committee for the American Heart Association's annual meeting, and frequently is asked to organize and speak at symposia and conferences.


    Dr Faber's recent work has found that the number and diameter of collaterals—unique "endogenous bypass vessels" that are present in brain, heart, lower extremities and other tissues—vary widely among healthy mice. This discovery is now finding confirmation in humans. A consequence is that individuals with poor collateral abundance suffer greater tissue injury and cell death when arterial occlusion occurs secondary to thrombosis, embolism or atherosclerosis. The result is much more severe stroke, myocardial infarction, ischemic heart disease, and peripheral artery disease. Current work by the Faber group is focused on determining the genetic and environmental factors responsible for this variation. They have identified a single genetic locus that is responsible for 75-85% of the variation in mice. Ongoing work is directed at identifying the underlying gene and the collaterogenesis pathway that it controls, and determining if a similar "risk allele" is responsible for collateral insufficiency in humans. Answers to these questions could provide novel diagnostic markers and therapeutic targets for stroke, heart disease, and peripheral artery disease.

    Dr. Faber received his PhD degree in Physiology from the University of Missouri in 1980. He then joined the laboratory of Dr. Michael Brody at the University of Iowa as a Postdoctoral Fellow in Pharmacology. In 1983 Dr. Faber became Assistant Professor in the Department of Cell and Molecular Physiology at University of North Carolina and was appointed Professor in 1994.

    « Previous  |  Next »



Workshop Organizer: NIH

NCI:Nancy Emenaker, PhD, RD
Suzanne Forry-Schaudies, PhD
NHLBI: Yunling Gao, MD, PhD
NIDDK: Teresa Jones, MD

NIH - National Institutes of Health: Turning Discovery Into Health


Back to top

Trans-NIH Angiogenesis header